VVUS VIVUS Inc.

2.81
+0.03  (+1%)
Previous Close 2.78
Open 2.77
Price To Book -0.82
Market Cap 29870084
Shares 10,629,923
Volume 57,931
Short Ratio
Av. Daily Volume 97,456

SEC filingsSee all SEC filings

  1. 8-K - Current report 181230992
  2. 8-K - Current report 181202048
  3. 8-K - Current report 181162986
  4. 8-K - Current report 181153864
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181153649

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved July 17, 2012.
Qnexa
Obesity
Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014
Avanafil
Erectile dysfunction
Phase 1 trial completed July 2018.
VI-0106
Pulmonary arterial hypertension (PAH)

Latest News

  1. 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
  2. The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
  3. Vivus (VVUS) Down 17% Since Last Earnings Report: Can It Rebound?
  4. New Research Coverage Highlights CommVault, Dawson Geophysical, RF Industries, Hennessy Advisors, VIVUS, and Semiconductor Manufacturing International — Consolidated Revenues, Company Growth, and Expectations for 2018
  5. Edited Transcript of VVUS earnings conference call or presentation 1-Nov-18 8:30pm GMT
  6. VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
  7. Vivus: 3Q Earnings Snapshot
  8. VIVUS Reports Third Quarter 2018 Financial Results
  9. VIVUS Adds Two New Members to the Board of Directors
  10. VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018
  11. VIVUS to Present at the BIO Investor Forum on October 17, 2018
  12. VIVUS Regains Compliance with Nasdaq Listing Requirements
  13. VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up
  14. VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb
  15. New Growth Opportunities Jump for 3 Biotech Stocks in 2018
  16. Why Is Vivus (VVUS) Down 6.4% Since Last Earnings Report?
  17. VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market

SEC Filings

  1. 8-K - Current report 181230992
  2. 8-K - Current report 181202048
  3. 8-K - Current report 181162986
  4. 8-K - Current report 181153864
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181153649
  6. 8-K - Current report 181142822
  7. S-8 - Securities to be offered to employees in employee benefit plans 181136479
  8. 8-K - Current report 181126493
  9. EFFECT - Notice of Effectiveness 181092428
  10. 8-K - Current report 181086865